Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
2.
J Exp Clin Cancer Res ; 41(1): 115, 2022 Mar 30.
Article in English | MEDLINE | ID: mdl-35354476

ABSTRACT

BACKGROUND: The inhibition of neddylation by the preclinical drug MLN4924 represents a new strategy to combat cancer. However, despite being effective against hematologic malignancies, its success in solid tumors, where cell-cell and cell-ECM interactions play essential roles, remains elusive. METHODS: Here, we studied the effects of MLN4924 on cell growth, migration and invasion in cultured prostate cancer cells and in disease-relevant prostate tumoroids. Using focused protein profiling, drug and RNAi screening, we analyzed cellular pathways activated by neddylation inhibition. RESULTS: We show that mechanical stress induced by MLN4924 in prostate cancer cells significantly affects the therapeutic outcome. The latter depends on the cell type and involves distinct Rho isoforms. In LNCaP and VCaP cells, the stimulation of RhoA and RhoB by MLN4924 markedly upregulates the level of tight junction proteins at cell-cell contacts, which augments the mechanical strain induced by Rho signaling. This "tight junction stress response" (TJSR) causes the collapse of cell monolayers and a characteristic rupture of cancer spheroids. Notably, TJSR is a major cause of drug-induced apoptosis in these cells. On the other hand, in PC3 cells that underwent partial epithelial-to-mesenchymal transition (EMT), the stimulation of RhoC induces an adverse effect by promoting amoeboid cell scattering and invasion. We identified complementary targets and drugs that allow for the induction of TJSR without stimulating RhoC. CONCLUSIONS: Our finding that MLN4924 acts as a mechanotherapeutic opens new ways to improve the efficacy of neddylation inhibition as an anticancer approach.


Subject(s)
Apoptosis , Neoplasms , Cell Proliferation , Humans , Male , NEDD8 Protein/metabolism , Stress, Mechanical
3.
Front Oncol ; 7: 293, 2017.
Article in English | MEDLINE | ID: mdl-29322028

ABSTRACT

A recent decline in the discovery of novel medications challenges the widespread use of 2D monolayer cell assays in the drug discovery process. As a result, the need for more appropriate cellular models of human physiology and disease has renewed the interest in spheroid 3D culture as a pertinent model for drug screening. However, despite technological progress that has significantly simplified spheroid production and analysis, the seeming complexity of the 3D approach has delayed its adoption in many laboratories. The present report demonstrates that the use of a spheroid model may be straightforward and can provide information that is not directly available with a standard 2D approach. We describe a cost-efficient method that allows for the production of an array of uniform spheroids, their staining with vital dyes, real-time monitoring of drug effects, and an ATP-endpoint assay, all in the same 96-well U-bottom plate. To demonstrate the method performance, we analyzed the effect of the preclinical anticancer drug MLN4924 on spheroids formed by VCaP and LNCaP prostate cancer cells. The drug has different outcomes in these cell lines, varying from cell cycle arrest and protective dormancy to senescence and apoptosis. We demonstrate that by using high-content analysis of spheroid arrays, the effect of the drug can be described as a series of EC50 values that clearly dissect the cytostatic and cytotoxic drug actions. The method was further evaluated using four standard cancer chemotherapeutics with different mechanisms of action, and the effect of each drug is described as a unique multi-EC50 diagram. Once fully validated in a wider range of conditions, this method could be particularly valuable for phenotype-based drug discovery.

4.
Cell Death Dis ; 7(12): e2505, 2016 12 01.
Article in English | MEDLINE | ID: mdl-27906189

ABSTRACT

Inhibition of protein degradation by blocking Cullin-RING E3 ligases (CRLs) is a new approach in cancer therapy though of unknown risk because CRL inhibition may stabilize both oncoproteins and tumor suppressors. Probing CRLs in prostate cancer cells revealed a remarkable plasticity of cells with TMPRSS2-ERG translocation. CRL suppression by chemical inhibition or knockdown of RING component RBX1 led to reversible G0/G1 cell cycle arrest that prevented cell apoptosis. Conversely, complete blocking of CRLs at a higher inhibitor dose-induced cytotoxicity that was amplified by knockdown of CRL regulator Cand1. We analyzed cell signaling to understand how varying degrees of CRL inhibition translated to distinct cell fates. Both tumor suppressor and oncogenic cell signaling pathways and transcriptional activities were affected, with pro-metastatic Wnt/ß-catenin as the most upregulated. Suppression of the NF-κB pathway contributed to anti-apoptotic effect, and androgen receptor (AR) and ERG played decisive, though opposite, roles: AR was involved in protective quiescence, whereas ERG promoted apoptosis. These data define AR-ERG interaction as a key plasticity and survival determinant in prostate cancer and suggest supplementary treatments that may overcome drug resistance mechanisms regulated by AR-ERG interaction.


Subject(s)
Cell Plasticity , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Signal Transduction , Ubiquitin-Protein Ligases/metabolism , Ubiquitins/metabolism , Cell Line, Tumor , Cell Lineage/drug effects , Cell Plasticity/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Cyclopentanes/pharmacology , Gene Knockdown Techniques , Humans , Male , Models, Biological , NEDD8 Protein , Pyrimidines/pharmacology , Receptors, Androgen/metabolism , Signal Transduction/drug effects , Spheroids, Cellular/drug effects , Spheroids, Cellular/pathology , Transcription, Genetic/drug effects , Transcriptional Regulator ERG/metabolism
5.
J Nanobiotechnology ; 14(1): 68, 2016 Sep 07.
Article in English | MEDLINE | ID: mdl-27604187

ABSTRACT

BACKGROUND: Photosensitizers are used in photodynamic therapy (PDT) to destruct tumor cells, however, their limited solubility and specificity hampers routine use, which may be overcome by encapsulation. Several promising novel nanoparticulate drug carriers including liposomes, polymeric nanoparticles, metallic nanoparticles and lipid nanocomposites have been developed. However, many of them contain components that would not meet safety standards of regulatory bodies and due to difficulties of the manufacturing processes, reproducibility and scale up procedures these drugs may eventually not reach the clinics. Recently, we have designed a novel lipid nanostructured carrier, namely Lipidots, consisting of nontoxic and FDA approved ingredients as promising vehicle for the approved photosensitizer m-tetrahydroxyphenylchlorin (mTHPC). RESULTS: In this study we tested Lipidots of two different sizes (50 and 120 nm) and assessed their photodynamic potential in 3-dimensional multicellular cancer spheroids. Microscopically, the intracellular accumulation kinetics of mTHPC were retarded after encapsulation. However, after activation mTHPC entrapped into 50 nm particles destroyed cancer spheroids as efficiently as the free drug. Cell death and gene expression studies provide evidence that encapsulation may lead to different cell killing modes in PDT. CONCLUSIONS: Since ATP viability assays showed that the carriers were nontoxic and that encapsulation reduced dark toxicity of mTHPC we conclude that our 50 nm photosensitizer carriers may be beneficial for clinical PDT applications.


Subject(s)
Mesoporphyrins/pharmacology , Photochemotherapy/methods , Spheroids, Cellular/drug effects , Cell Survival/drug effects , Cell Survival/radiation effects , Drug Carriers/administration & dosage , Emulsions/pharmacology , Humans , Lipids/chemistry , Materials Testing , Mesoporphyrins/administration & dosage , Nanoparticles/chemistry , Particle Size , Spheroids, Cellular/radiation effects , Tumor Cells, Cultured
6.
J Biomed Opt ; 19(3): 36004, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24599086

ABSTRACT

Quantification of cell proliferation and monitoring its kinetics are essential in fields of research such as developmental biology, oncology, etc. Although several proliferation assays exist, monitoring cell proliferation kinetics remains challenging. We present a novel cell proliferation assay based on real-time monitoring of cell culture inside a standard incubator using a lensfree video-microscope, combined with automated detection of single cell divisions over a population of several thousand cells. Since the method is based on direct visualization of dividing cells, it is label-free, continuous, and not sample destructive. Kinetics of cell proliferation can be monitored from a few hours to several days. We compare our method to a standard assay, the EdU proliferation assay, and as proof of principle, we demonstrate concentration-dependent and time-dependent effect of actinomycin D-a cell proliferation inhibitor.


Subject(s)
Cell Proliferation , Cytological Techniques/instrumentation , Cytological Techniques/methods , Microscopy, Video/instrumentation , Microscopy, Video/methods , Animals , Cells, Cultured , Kinetics , Mice , NIH 3T3 Cells
7.
J Biomed Opt ; 18(10): 101311, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23900442

ABSTRACT

A new contrast agent, LipImage™ 815, has been designed and compared to previously described indocyanine green (ICG)-loaded lipid nanoparticles (ICG-lipidots®). Both contrast agents display similar size (50-nm diameter), zeta potential, high IC50 in cellular studies, near-infrared absorption and emission wavelengths in the "imaging window," long-term shelf colloidal and optical stabilities with high brightness (>106 L mol-1 cm-1) in ready-to-use storage conditions in aqueous buffer (4°C in dark), therefore being promising fluorescence contrast agents for in vivo imaging. However, while ICG-lipidots® display a relatively short plasma lifetime, LipImage™ 815 circulates in blood for longer times, allowing the efficient uptake of fluorescence signal in human prostate cancer cells implanted in mice. Prolonged tumor labeling is observed for more than 21 days.


Subject(s)
Fluorescent Dyes/chemistry , Lipids/chemistry , Nanoparticles/chemistry , Optical Imaging/methods , Spectroscopy, Near-Infrared/methods , Animals , Cell Line, Tumor , Cell Survival/drug effects , Female , Fluorescent Dyes/pharmacokinetics , Fluorescent Dyes/toxicity , Humans , Lipids/pharmacokinetics , Male , Mice , Mice, Nude , Particle Size , Tissue Distribution
8.
J Biomed Nanotechnol ; 8(4): 594-604, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22852469

ABSTRACT

Considering toxicity requirements for clinical translation of fluorescence imaging applications, the use of biocompatible carriers for designing near infrared emitting contrast agents appears as an attractive alternative to semiconductor nanocrystals. Lipid nanoparticles (LNP) have been designed to serve as carriers for indocyanine green (ICG), the presently only human-use approved near infrared dye. The cytotoxicity and hemocompatibility of these nanoparticle-based probes are determined in vitro, respectively in mouse 3T3 fibroblasts and human blood samples. Comparative biodistribution of free ICG and ICG-LNP in mice is monitored, and an ex vivo fluorescence organ quantification is performed considering large animal cohorts. Good tolerability and very low hemolytic activity are demonstrated for naked and ICG-loaded LNP. Interestingly, ICG-LNP lead to long-term plasma fluorescence (> 24 hours) but also a partial intestinal reabsorption of ICG between 5 and 24 hours after injection. This novel ICG nanoformulation is foreseen to expand rapidly the field of clinical fluorescence imaging applications.


Subject(s)
Indocyanine Green/pharmacokinetics , Indocyanine Green/toxicity , Lipids/pharmacokinetics , Lipids/toxicity , Nanoparticles/chemistry , Animals , Cell Survival/drug effects , Cells, Cultured , Erythrocytes/drug effects , Female , Fluorescence , Hemolysis/drug effects , Humans , Indocyanine Green/chemistry , Lipids/chemistry , Mice , Mice, Nude , NIH 3T3 Cells , Nanoparticles/toxicity , Tissue Distribution
9.
J Biomed Opt ; 16(9): 096013, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21950927

ABSTRACT

The use of fluorescent nanostructures can bring several benefits on the signal to background ratio for in vitro microscopy, in vivo small animal imaging, and image-guided surgery. Fluorescent quantum dots (QDs) display outstanding optical properties, with high brightness and low photobleaching rate. However, because of their toxic element core composition and their potential long term retention in reticulo-endothelial organs such as liver, their in vivo human applications seem compromised. The development of new dye-loaded (DiO, DiI, DiD, DiR, and Indocyanine Green (ICG)) lipid nanoparticles for fluorescence imaging (lipidots) is described here. Lipidot optical properties quantitatively compete with those of commercial QDs (QTracker(®)705). Multichannel in vivo imaging of lymph nodes in mice is demonstrated for doses as low as 2 pmols of particles. Along with their optical properties, fluorescent lipidots display very low cytotoxicity (IC(50) > 75 nM), which make them suitable tools for in vitro, and especially in vivo, fluorescence imaging applications.


Subject(s)
Diagnostic Imaging/methods , Fluorescent Dyes/chemistry , Nanoparticles/chemistry , Soybean Oil/chemistry , Spectrometry, Fluorescence/methods , Analysis of Variance , Animals , Cell Survival , Contrast Media/chemistry , Lymph Nodes/chemistry , Lymph Nodes/metabolism , Mice , Mice, Nude , NIH 3T3 Cells , Particle Size , Phospholipids/chemistry , Quantum Dots , Surface-Active Agents/chemistry , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...